Skip to main content

Table 1 Characteristics of patients

From: Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China

Parameter

Total

KTX-HD

KTX

DAA-KTX

KTX-DAA

Patients

26

11

7

8

Age, years [mean ± SD]

49.0 ± 9.6

52.6 ± 10.0

39.7 ± 5.5

52.1 ± 6.6

Gender (male) [n (%)]

19 (73.1)

8 (72.7)

5 (71.4)

6 (75.0)

Transplant frequency [n (%)]

 1

12 (46.2)

6 (54.5)

2 (28.6)

4 (50.0)

 2

12 (46.2)

5 (45.5)

4 (57.1)

3 (37.5)

 ≥3

2 (7.7)

0 (0.0)

1 (14.3)

1 (12.5)

HCV genotype [n (%)]

 1b

21 (80.8)

10 (90.9)

5 (71.4)

6 (75.0)

 2a

5 (19.2)

1 (9.1)

2 (28.6)

2 (25.0)

 Cirrhosis [n (%)]

1 (3.8)

0 (0.0)

0 (0.0)

1 (12.5)

Immunosuppressive regimens [n (%)]

 Triple-therapy

18 (69.2)

3 (27.3)

7 (100.0)

8 (100.0)

 Double-therapy

6 (23.1)

6 (54.5)

0 (0.0)

0 (0.0)

 Monotherapy

2 (7.7)

2 (18.2)

0 (0.0)

0 (0.0)

DAAs regimens [n (%)]

 SOF

1 (3.8)

0 (0.0)

1 (14.3)

0 (0.0)

 SOF + LDV

17 (65.4)

8 (72.7)

4 (57.1)

5 (62.5)

 SOF + DCV

8 (30.8)

3 (27.3)

2 (28.6)

3 (37.5)

 Viral load, log10 IU/ml [mean ± SD]

6.5 ± 1.3

5.9 ± 1.1

6.5 ± 0.5

7.2 ± 1.6

 Treatment cycle, weeks [median (range)]

12 (12-12)

12 (12-12)

12 (12-12)

12 (12-24)